Clinical Trial Record

Return to Clinical Trials

Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer


2025-07-29


2026-12-29


2026-12-29


168

Study Overview

Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer

This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection.

Serum uric acid is a risk factor for gallbladder cancer in men and has a strong effect on pancreatic cancer in women. It has also been shown that elevated intracellular serum uric acid can induce an inflammatory stress response, which may promote its transformation, while elevated extracellular serum uric acidy further stimulate tumor cell proliferation, migration, and survival, and promote the development of highly aggressive cancer. In this study, the changes of serum uric acid before and after surgery was used as a prognostic marker for the survival of pancreatic cancer patients.

  • Serum Uric Acid
  • DIAGNOSTIC_TEST: serum uric acid test
  • SUA-PC

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2025-07-21  

N/A  

2025-07-21  

2025-07-21  

N/A  

2025-07-29  

2025-07-29  

N/A  

2025-07  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A


Allocation:
N/A


Interventional Model:
N/A


Masking:
N/A


Arms and Interventions

Participant Group/ArmIntervention/Treatment
: High serum uric acid

The increase of after serum uric acid operation compared with that before operation is≥10% Normal levels serum uric acid are typically 178 to 360 μm (3 to 6.8 mg/dl).

DIAGNOSTIC_TEST: serum uric acid test

  • Detect the serum uric acid in blood sample
: Low serum uric acid

The increase of after serum uric acid operation compared with that before operation < 10% Normal serum uric acid levels are typically 178 to 360 μm (3 to 6.8 mg/dl).

DIAGNOSTIC_TEST: serum uric acid test

  • Detect the serum uric acid in blood sample
Primary Outcome MeasuresMeasure DescriptionTime Frame
Overall survivalOverall survival was defined as the time from diagnosis to death.3-5 years
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Recurrence-free survivalRecurrence-free survival is the length of time from either the date of diagnosis or the start of therapy for a disease to the date of the first loco-regional or systemic recurrence.3-5 years
Cost of hospitalizationThe cost of the first hospitalization from admission to discharge.3 months
Length of hospital stayThe first day of hospitalization for the first admission to the last day of discharge.3 months
Pancreatic fistulaWhether or not pancreatic-intestinal anastomotic leakage occurred at the time of the first hospitalization.3 months
Biliary fistulaWhether or not a biliary-intestinal anastomotic leak occurred at the time of the first hospitalization.3 months
BleedingWhether or not there was bleeding after the first inpatient surgery.3 months
Abdominal cavity infectionWhether or not there was an abdominal infection after the first inpatient surgery.3 months

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Wenbo Meng, M.D. Ph. D.

Phone Number: 13919177177

Email: mengwb@163.com

Study Contact Backup

Name: Zhengping An, M.D.

Phone Number: 18298415512

Email: anzhp2023@lzu.edu.cn

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:

  • Patients with pathologically confirmed pancreatic cancer (primary)
  • Patients who underwent Radical resection of pancreatic cancer(Pancreaticoduodenectomy or Distal pancreatectomy)
  • The postoperative survival time was at least 6 weeks

  • Exclusion Criteria:

  • No surgery was performed, or only palliative surgery/ biopsy was performed
  • Patients who underwent emergency hemodialysis or plasma exchange after surgery
  • History of gout or long-term urate-lowering therapy, such as allopurinol
  • Patients are missing follow-up data
  • Hydrochlorothiazide and furosemide were used
  • Chronic kidney disease
  • Oncolytic syndrome
  • Hemolytic anemia
  • Lead poisoning
  • Hyperparathyroidism
  • Hypothyroidism
  • A tyrosinase inhibitor was used
  • Patients with nonpancreatic primary tumors
  • Pregnant or postpartum women.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.


    • PRINCIPAL_INVESTIGATOR: Wenbo Meng, M.D. Ph. D., Hepatopancreatobiliary Surgery Institute of Gansu Province

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    • Huang CF, Huang JJ, Mi NN, Lin YY, He QS, Lu YW, Yue P, Bai B, Zhang JD, Zhang C, Cai T, Fu WK, Gao L, Li X, Yuan JQ, Meng WB. Associations between serum uric acid and hepatobiliary-pancreatic cancer: A cohort study. World J Gastroenterol. 2020 Nov 28;26(44):7061-7075. doi: 10.3748/wjg.v26.i44.7061.
    • Fini MA, Elias A, Johnson RJ, Wright RM. Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med. 2012 Aug 15;1(1):16. doi: 10.1186/2001-1326-1-16.